Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post earnings of $0.10 per share when it actually produced earnings of $0.10, delivering no surprise.Over the last four quarters, the company has su ...

Fox Corporation (NASDAQ: FOX , NASDAQ: FOXA ) just delivered one of its most headline-friendly quarters in years. Revenue surged 27% YoY to $4.37 billion, and adjusted EPS came in at $1.10, beating expectations by a wide margin. But while the top-line beat was impressive, theI’m passionate about finance and investing, focusing on business analysis, fundamental analysis, valuation, and long-term growth, especially in sectors like AI, fintech, finance and tech. I study finance and economy and have hands-on ex ...

Jason and Travis Kelce with Dunkin Donuts on the New Heights podcast.Amazon's second-ever Upfronts pitch to advertisers this week featured an appearance by NFL champion brothers Jason and Travis Kelce. They weren't there to hype live football rights.While Amazon's Prime owns the media rights to the NFL's Thursday Night Football games — and the streamer showcased much of its sports portfolio, including the upcoming NBA season, during the annual media presentations — the Kelce brothers were invited onstage be ...

I have been covering PennantPark Floating Rate Capital (NYSE: PFLT ) since December 2023. My initial piece was bullish, which followed by a series of follow-up positive reviews. Also, the latest article was concluded by positive takeawaysRoberts Berzins has over a decade of experience in the financial management helping top-tier corporates shape their financial strategies and execute large-scale financings. He has also made significant efforts to institutionalize REIT framework in Latvia to boost the liquid ...

Core Insights - Silynxcom Ltd. reported a record revenue of $9.1 million for the year ended December 31, 2024, reflecting an 18% increase from the previous year, driven by ongoing expansion and product adoption [6] - The company has introduced innovative products, including an armored personnel carrier headset that enhances battlefield awareness by detecting drone noise while maintaining hearing protection [6] - Silynxcom has received $10 million in orders from the Israel Defense Forces since October 7, 2023, indicating strong demand for its products [6] Financial Highlights - Revenues for 2024 reached $9.1 million, up approximately 18% from the previous year [6] - Gross profit for the year was approximately $3.8 million, a 17% increase compared to $3.2 million in the previous year [6] - Cash and cash equivalents as of December 31, 2024, totaled $3.2 million [6] Corporate Developments - The company closed an underwritten public offering on April 2, 2025, generating gross proceeds of approximately $2.9 million [6] - Silynxcom expanded its sales operations in the Asia Pacific region, enhancing its market presence [6] - The company successfully completed field trials for its innovative in-ear communication solution aimed at boosting situational awareness and safety for military personnel [6]

Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6 to 17 [4] - The company's devices have received FDA clearance for treating all severity levels of OSA in adults and moderate to severe OSA in children [4] - Vivos' CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children [4] Industry Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed [5] - The disorder is linked to various serious chronic health conditions, indicating a significant unmet need in the market for effective treatment solutions [5] - Current solutions often fail to address the root causes of OSA, highlighting the importance of innovative approaches like those offered by Vivos [5] Upcoming Events - Vivos plans to release its first quarter 2025 financial results after market close on May 15, 2025, followed by a conference call at 5:00 p.m. ET to discuss the results and recent developments [1] - The conference call can be accessed via a dedicated phone line and will also be available as a live webcast on the company's website [2][3] Innovative Approach - The Vivos Method provides a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, aiming to improve patient outcomes in sleep health [7] - The company collaborates with healthcare providers, including dentists and sleep specialists, to address the complex needs of patients suffering from sleep-related disorders [6]

Core Insights - Renovaro Inc. has launched Augusta, a Precision Neurology Platform aimed at improving patient stratification, biomarker discovery, and drug validation in neurology, an area that has historically faced challenges in diagnosis and treatment [1][2] Group 1: Platform Features - Augusta integrates multimodal data analytics with proprietary in silico screening, significantly reducing the time required for identifying biomarkers and therapeutics compared to conventional methods [1] - The platform emphasizes interpretability, clinical alignment, and rigorous benchmarking, moving away from black-box approaches [2] - Its modular infrastructure allows for plug-and-play model evaluation, including large language models conditioned with proprietary knowledge graphs, fostering continuous innovation while ensuring clinical robustness [2] Group 2: Validation and Efficacy - The efficacy of Augusta has been demonstrated in Parkinson's Disease through phenoclustering, which identified novel patient subgroups with unique clinical characteristics and biomarkers [3] - In epilepsy, the platform has successfully identified novel lead compounds targeting patient populations with rare genetic mutations [3] Group 3: Future Plans - Renovaro plans to expand its precision neurology efforts into additional neurological disorders and is currently discussing strategic partnerships with academic medical centers and life sciences companies [4] Group 4: Company Overview - Renovaro aims to accelerate precision and personalized medicine for longevity by leveraging AI and biotechnology platforms for early diagnosis, targeted treatments, and drug discovery [5]

- The #1 brand of siding in North America* becomes preferred siding and trim supplier for Davidson Homes -CHICAGO, May 14, 2025 /PRNewswire/ -- James Hardie Building Products Inc. (James Hardie), a subsidiary of James Hardie Industries plc (ASX: JHX) (NYSE: JHX) and the North American leader in fiber cement home siding and exterior design solutions, today announced a groundbreaking three-year exclusive agreement with Davidson Homes. Under this deal, James Hardie will provide its renowned Hardie® siding and ...

You might soon be able to take a Southwest Airlines flight to Europe. On Tuesday, the budget airline asked the Department of Transportation for permission to fly to any country with which the US has an Open Skies agreement.The State Department lists 123 such countries, representing most of the world. Meanwhile, Southwest currently serves 10 countries outside the US. Other than Mexico, they are all in Central America or the Caribbean.Open Skies agreements allow airlines to operate between two countries w ...

Radcom (RDCM) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.64%. A quarter ago, it was expected that this monitoring service for the communications industry would post earnings of $0.19 per share when it actually produced earnings of $0.23, delivering a surprise of 21.05%.Over th ...